Estudo randomizado | Baricitinibe reduziu a mortalidade em adultos hospitalizados com COVID-19.

Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial – The Lancet Respiratory Medicine

Comentários:

Baricitinib: the first immunomodulatory treatment to reduce COVID-19 mortality in a placebo-controlled trial – The Lancet Respiratory Medicine

Rheumatoid Arthritis Drug Combined with Standard of Care May Help Reduce Mortality for Hospitalized COVID-19 Patients – Vanderbilt University Medical Center

Comentários no Twitter

NEW—Baricitinib did not improve the composite primary endpoint of progression to NIV,
high-flow O2, IMV, or death; however, it did reduce 28-day all-cause mortality by 38·2% vs placebo (HR 0·57 [95% CI 0·41–0·78])

Read the COV-BARRIER study: https://t.co/QrU6GW0XcQ#ISICEM2021

— The Lancet Respiratory Medicine (@LancetRespirMed) September 1, 2021

(thread – click for more)

1/🧵💥 NEW COVID THERAPY SAVES LIVES

Adding baricitinib to steroids will save 1,000s of hospitalized #COVID pts. Our @LancetRespirMed COV-Barrier study is FREE.

I explain👇why it’s such a great #Pandemic discovery story: a new way to ⬇️ COVID19 deaths.https://t.co/8I5BlwyT2R pic.twitter.com/6KcfQrljqC

— WesElyMD (@WesElyMD) September 1, 2021